XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies
Summary
XtalPi announced that its collaboration with DoveTree Medicines has advanced and that it received a second contractual payment of $19 million. The partners have transferred patents tied to the initial pipeline and moved one preclinical candidate into IND-enabling studies. The deal could ultimately reach up to $5.99 billion if programs succeed, and XtalPi remains eligible for future milestones and royalties. The announcement highlights XtalPi’s AI-, physics-, and automation-driven discovery platform and its role in accelerating drug development.
Classifications
industries
Energy & Natural Resources
applications
Business Intelligence
AskAI Classifications
Labels
Warehouse Control System Software
Material Handling Software
Automation Software
Linked Companies
Dove Tree Canyon Software, Inc.
up to $1M
XtalPi
$10M to $25M